Taking Action on Pull Incentives in Norway

Read the Full Report (English)

Key Messages:

• Antimicrobial resistance is a growing health concern, both across the globe where it is attributed with 1.27 million deaths each year and associated with 4.95 million, and in Norway with at least 240 attributable deaths and 990 associated deaths each year.

• The pipeline of new antimicrobials has grown increasingly thin and is inadequate to provide the vital new medicines that are needed to treat drug-resistant infections.

• By establishing pull incentive schemes both nationally and in cooperation with Nordic, European, and global partners, Norway can play an important role in reinvigorating the antimicrobial pipeline and ensuring patients have access to adequate treatments.

• Based on the disease burden attributable to AMR, we model that Norway’s contribution to financing a global pull incentive scheme aimed at incentivising the development of and securing access to 18 new antimicrobials over 30 years would conservatively: 

  • Save at least 140 lives, generate €124 million in total benefits and yield an ROI of 1.5:1 over a 10-year period in Norway,

  • Save at least 2,700 lives, generate €1.94 billion in total benefits and yield an ROI of 6.9:1 over a 30-year period in Norway,

• Additionally, Norway’s contribution to the pull incentive scheme would represent saving over 5,800 lives in 10 years and over 112,000 lives in 30 years globally, through the new antimicrobials developed from the incentive program.

• Such a scheme would cost Norway an estimated €33 million per drug over a 10 year period, representing its “fair share” of a pull incentive basket funded by the G7, the EU and Norway.